Solara Active Pharma Sciences Ltd (SOLARA) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a strong quarter, achieving its highest EBITDA and PAT in the last 18 quarters, underscoring the strength of its core business and disciplined execution.
- Overall revenue grew by 20% year-on-year, driven primarily by the robust performance of the base business, which saw a 24% YoY revenue increase.
- The company demonstrated significant progress in strengthening its balance sheet, reducing its net debt by INR 135 crores during the quarter, a 22% reduction.
- Despite geopolitical headwinds in West Asia causing raw material price pressures and supply chain challenges, the company successfully managed costs to deliver an improved EBITDA margin of 17%.
- The commodity Ibuprofen business continues to face profitability challenges with a negative EBITDA margin, though a strategic review is underway with an expected resolution by H1 FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.